echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Focus: The annual reports of domestic pharmaceutical companies have been released one after another. How is the commercialization of blockbuster products?

    Focus: The annual reports of domestic pharmaceutical companies have been released one after another. How is the commercialization of blockbuster products?

    • Last Update: 2022-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    2021 can be described as a bumper year for innovative drugs in China.
    According to NMPA statistics, a total of 24 innovative drugs have been approved for marketing in China in 2021, hitting a new high in the past three years

    .
    Among them, there are a number of high-profile drugs, such as the first domestic ADC drug, Vidicitumumab, and two CAR-T products, Akilence Injection and Rekilenza Injection

    .
    However, the high light of research and development does not mean the success of commercialization.
    On the contrary, the research and development of innovative drugs is entering an embarrassing situation.
    On the one hand, the investment in new drug research and development is constantly pushing up, and on the other hand, it is the cold commercialization reality

    .
    For this batch of newly launched drugs in 2021, how will they perform in 2021? It's corporate annual report season, so let's find out

    .

    List of blockbuster product sales

    List of blockbuster product sales

    Table: Sales Revenue of Listed Varieties in 2021

    Data source: company annual report

    01 Nuocheng Jianhua: Orbrutinib

    01 Nuocheng Jianhua: Orbrutinib

    Orelabrutinib is a selective Bruton tyrosine kinase inhibitor
    .
    In January 2021, the NMPA approved the marketing application for orelabrutinib for the treatment of r/r CLL/SLL and r/r MCL

    .
    In 2021, Orbrutinib will achieve sales revenue of 241 million yuan
    .
    In December 2021, orelabrutinib was included in the National Medical Insurance Drug List
    .

    In 2021, Orbrutinib will achieve sales revenue of 241 million yuan
    .

    Comments: In the face of the first-mover advantage of ibrutinib and zanubrutinib, orbrutinib showed good resilience and achieved sales of 241 million yuan in the first year, which is dazzling
    .
    In July 2021, Nuocheng Jianhua issued a license to Bojian for US$940 million to outsource the global exclusive rights of Orelabrutinib in the field of multiple sclerosis, as well as the exclusive rights of some autoimmune diseases outside of China, marking Orbutitinib Nepal's official "going to sea"

    .
    With the inclusion of Obrutinib in medical insurance, the future space is even wider

    .
    China's BTK TKI field has officially entered a "three-legged" competition

    .

    Comments:

    02Zai Lab: Ripatinib

    02Zai Lab: Ripatinib

    Ripatinib, an oral switch-regulated kinase inhibitor of KIT and PDGFRA kinases, has been approved in nine regions for the treatment of fourth-line advanced gastrointestinal stromal tumors (GIST)
    .
    Zai Lab obtained an exclusive license in 2019 to develop and commercialize ripatinib in Greater China

    .
    In March 2021, the National Medical Products Administration approved the marketing application of ripatinib

    .
    In 2021, Ripatinib will achieve revenue of $11.
    62 million

    .

    In 2021, Ripatinib will achieve revenue of $11.
    62 million

    .

    Comments: In November 2021, Deciphera announced preliminary results for the second-line treatment of GIST with ripatinib, which did not meet the primary endpoint of improving progression-free survival compared with sunitinib
    .
    This is undoubtedly a blow to the future development of Ripatinib

    .

    Comments:

    03 Corning Jerry: Envolumab (KN035)

    03 Corning Jerry: Envolumab (KN035)

    Envolizumab is a recombinant humanized PD-L1 single-domain antibody Fc fusion protein injection, the world's first subcutaneous PD-L1 inhibitor
    .
    On November 25, 2021, the State Food and Drug Administration officially approved the marketing of nvolimumab for adults with unresectable or metastatic microsatellite high instability/mismatch repair deficiency (MSI-H/dMMR).
    Treatment of patients with advanced solid tumors

    .
    On December 8, the first batch of prescriptions for nvolimumab landed

    .
    As of December 31, 2021, the company has achieved sales revenue of 146 million yuan, of which envolimab has achieved sales revenue of 4.
    4 million yuan

    .

    As of December 31, 2021, the company has achieved sales revenue of 146 million yuan, of which envolimab has achieved sales revenue of 4.
    4 million yuan

    .

    Comments: The company's 146 million yuan operating income includes four parts, namely sales of pharmaceuticals, royalties, license fees, and the provision of goods and consumables for R&D projects.
    Among them, license fee income reached 133 million yuan, which is The project with the highest proportion is mainly due to Corning Jereh's signing of a license agreement with Jinmante Biotechnology in August 2021; the royalties amounted to 7.
    2 million yuan, mainly from the company's cooperation with Sidi Pharmaceutical and Sichuan in December 2021.
    The license to authorize the intellectual property rights of KN035 signed by Thinking Kangrui Pharmaceutical; the sales of Enwo's monoclonal antibody realized an income of 4.
    4 million yuan

    .

    Comments:

    04 Rongchang Bio: Vidicitumab for Injection

    04 Rongchang Bio: Vidicitumab for Injection

    Vidicitumab for injection is an innovative antibody-drug conjugate (ADC) independently developed in China, which contains human epidermal growth factor receptor-2 (HER2) antibody part, linker and cytotoxic drug monomethyl auristatin E (MMAE), which provides a new treatment option for patients with locally advanced or metastatic gastric cancer
    .
    In 2021, Vidicitumab for injection will achieve sales of 84 million yuan , covering 374 hospitals and about 2,139 patients in 105 prefecture-level cities in 29 provincial administrative units across the country
    .
    Vidicitumab for injection received conditional marketing approval on June 9, 2021, and sales began in July

    .

    In 2021, Vidicitumab for injection will achieve sales of 84 million yuan

    Comments: The sales of 84 million yuan have been achieved within half a year of listing, and Vidicitumumab has achieved remarkable results
    .
    More benefits are waiting for this domestic ADC drug.
    First, the indication for urothelial cancer will be added in January 2022; second, it will successfully enter the medical insurance catalogue and become the only ADC drug included in the medical insurance; third, the company strengthens the team construction

    .
    We believe Vidicitumab will reach a new level in 2022

    .

    Comments:

    05 WuXi Ju Nuo: Ruiki Orenza Injection

    05 WuXi Ju Nuo: Ruiki Orenza Injection

    Ruiki Orenza Injection is a CD19-targeting CAR-T cell therapy independently developed by WuXi Juno on the basis of JCAR017 from Juno in the United States.
    It was approved for marketing on September 3, 2021 for the treatment of r/r LBCL in adult patients after second-line or more systemic therapy

    .
    As of December 31, 2021, Ruijilunsai injection has achieved a revenue of 30.
    8 million yuan

    .

    As of December 31, 2021, Ruijilunsai injection has achieved a revenue of 30.
    8 million yuan

    .

    As of February 2022, the company has established a team of 110 employees, covering sales team, marketing team, hospital access team,
    etc.
    In 2021, a total of 54 prescriptions for Ruiki Aurenzai Injection have been issued, and 30 patients have been reinfused

    .
    In addition, Ruiki Orenza injection has been included in 44 commercial insurance products and 16 municipal supplementary medical insurance plans

    .

    Comments: 2021 is the first year of CAR-T cell therapy in China, and CAR-T cell therapy is still in the process of exploration
    .
    After WuXi Junuo's Ruiki Orenza injection was launched, the company rapidly expanded its team, obtained 54 prescriptions within a few months, and included 44 commercial insurance products and 16 prefecture-level supplementary medical insurance plans.

    .
    However, the cost increase brought by commercialization is also obvious.
    The company's annual report discloses that sales and marketing staff costs have increased by 70 million yuan, and business activity expenses have also increased by 47.
    4 million yuan

    .
    The author believes that the development of CAR-T cell therapy in China is still "a long way to go"

    .

    Comments:

    06 Fosun Kite: Achilles Injection

    06 Fosun Kite: Achilles Injection

    Achilles injection is an autologous immune cell injection prepared from autologous targeting human CD19 chimeric antigen receptor T cells (CAR-T) genetically modified with a retroviral vector carrying the CD19 CAR gene
    .
    Fosun Pharma has not disclosed the specific sales of akirenzai injection , but disclosed in its annual report that as of the end of February 2022, akirenzai injection has been listed in 23 provinces and cities in Huimin Insurance and more than 40 cities.
    There are 75 registered treatment centers, and about 100 patients have entered the treatment process

    .

    Fosun Pharma has not disclosed the specific sales of akilenxe injection

    Comments: Yescarta achieved global sales of US$695 million in 2021, a year-on-year increase of 23.
    44%

    .
    At present, 4 CD19 CAR-T cell therapies have been approved for the market in the world, and the competition is becoming fierce.
    Breyanzi, which will debut in 2021, has only achieved sales of 87 million US dollars, and has been left behind by the first-tier products

    .

    Comments:

    07 Rongchang Bio: Taitahip

    07 Rongchang Bio: Taitahip

    Taitacept is a TACI-Fc fusion protein independently developed by Rongchang Bio.
    It can inhibit two cytokines, BLyS and APRIL at the same time.
    It has a new drug structure and dual-target mechanism of action.
    Various autoimmune diseases such as rheumatoid arthritis

    .
    In 2021, Taitahip will achieve sales revenue of 47.
    3 million yuan

    .
    In December 2021, Taitacept was included in the National Medical Insurance Directory
    .

    In 2021, Taitahip will achieve sales revenue of 47.
    3 million yuan

    .

    Comments: As of December 31, 2021, the company has a total of 132 Taitahip sales teams, and the company has decided to continue to expand the sales team in 2022
    .
    In addition, the phase II clinical study of tetacept in primary Sjögren's syndrome (pSS) has achieved positive results, and the company also launched the phase III study of tetacept in the treatment of SLE in the United States in March 2022, and the drug will be sold overseas Just around the corner

    .
    Inclusion in health insurance is also expected to boost the volume of tacitabine

    .

    Comments:

    summary

    summary

    Judging from the sales of listed drugs in 2021, Nuochengjianhua's orelabrutinib has won the top spot with sales of 241 million yuan, and the results can be described as dazzling
    .
    In recent years, the ADC and CAR-T drugs that have become popular in recent years have also achieved impressive results in the first year, but there is still a gap between them and small molecule drugs

    .
    Regarding the gap between drug R&D and commercialization mentioned at the beginning, the author believes that for innovative drug companies, on the
    one hand, they need to strengthen their commercialization capabilities , including medical insurance negotiation, pricing strategy, government affairs, hospital sales, etc.
    We have also seen a number of Enterprises are actively including drugs in the national medical insurance list, and achieve sales growth by exchanging volume for price; on the
    other hand, through the overseas development of drugs to achieve leapfrog development , such as Nuochengjianhua to Bojian License out of Orbuti with US$940 million.
    Nicholas has the exclusive global power in the field of multiple sclerosis, and successfully overtakes the corner

    .

    On the one hand, it is necessary to strengthen commercialization capabilities , and on the other hand, to achieve leapfrog development through drug delivery
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.